- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06749457
Une étude visant à évaluer l'innocuité et la pharmacocinétique de l'AZD7760 chez des adultes en bonne santé (phase I) et des adultes atteints d'insuffisance rénale terminale sous hémodialyse avec un cathéter veineux central (phase IIa) (PEAK)
Une étude de phase I/IIa randomisée, en double aveugle et contrôlée par placebo pour évaluer l'innocuité et la pharmacocinétique de l'AZD7760 chez des participants en bonne santé et chez des patients atteints d'insuffisance rénale terminale recevant une hémodialyse via un cathéter veineux central
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.
Study details include:
- A 28-day Screening Period.
- A Dosing Period of 3 days in which a single intravenous infusion will be given on Day 1.
- A Follow-up Period of 12 months from the time of administration of the study intervention.
In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.
Study details include:
- A 28-day Screening Period.
- A Dosing Period in which 2 intravenous infusions will be given 3 months apart (Day 1 and Day 91).
- A Follow-up Period of 12 months after the last administration of the study intervention on Day 91.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Huntsville, Alabama, États-Unis, 35805
- Research Site
-
-
California
-
Chula Vista, California, États-Unis, 91910
- Research Site
-
Glendale, California, États-Unis, 91206
- Research Site
-
Granada Hills, California, États-Unis, 91344
- Research Site
-
Los Angeles, California, États-Unis, 90027
- Research Site
-
Northridge, California, États-Unis, 91324
- Research Site
-
Northridge, California, États-Unis, 91325
- Research Site
-
Oxnard, California, États-Unis, 93036
- Research Site
-
Riverside, California, États-Unis, 92503
- Research Site
-
San Dimas, California, États-Unis, 91773
- Research Site
-
Tarzana, California, États-Unis, 91356
- Research Site
-
Valencia, California, États-Unis, 91355
- Research Site
-
Victorville, California, États-Unis, 92392
- Research Site
-
-
Colorado
-
Englewood, Colorado, États-Unis, 80110
- Research Site
-
-
Florida
-
Bradenton, Florida, États-Unis, 34209
- Research Site
-
Coral Springs, Florida, États-Unis, 33071
- Research Site
-
Hollywood, Florida, États-Unis, 33024
- Research Site
-
Orlando, Florida, États-Unis, 32806
- Research Site
-
Tampa, Florida, États-Unis, 33603
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, États-Unis, 30046
- Research Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60640
- Research Site
-
Chicago, Illinois, États-Unis, 60643
- Research Site
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21225
- Research Site
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Research Site
-
Pontiac, Michigan, États-Unis, 48341
- Research Site
-
-
Mississippi
-
Tupelo, Mississippi, États-Unis, 38801
- Research Site
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64111
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68510
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89128
- Research Site
-
-
New Jersey
-
Jersey City, New Jersey, États-Unis, 07305
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87109
- Research Site
-
-
New York
-
Ridgewood, New York, États-Unis, 11385
- Research Site
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27103
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, États-Unis, 18017
- Research Site
-
-
Texas
-
Beaumont, Texas, États-Unis, 77706
- Research Site
-
Dallas, Texas, États-Unis, 75246
- Research Site
-
Houston, Texas, États-Unis, 77074
- Research Site
-
McAllen, Texas, États-Unis, 78503
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Phase I:
- Participant must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.
- Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.
- Healthy participants with no clinically significant concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as per the judgement of the investigator.
Phase IIa:
-
Participant must be ≥ 18 years of age at the time of signing the informed consent.
-
Participants who meet all of the following disease status requirements:
- Diagnosed with End-stage kidney disease (ESKD).
- Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.
- Receiving hemodialysis for treatment of ESKD for at least 60 days before randomization.
- At least 3 previous dialysis sessions using current dialyzer.
- Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2 within the last 30 days.
- No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.
- Not taking long-term systemic antibiotics with activity against S aureus.
Exclusion Criteria:
Phase I:
- Known hypersensitivity to any component of the study intervention
- Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
- Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
- Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upper limit of normal (ULN) at screening. Testing may be repeated once at the investigator's discretion.
- Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.
- Hemoglobin or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.
- White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.
- History of malignancy other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
- Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
- Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.
- Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.
- Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
- Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).
- Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.
- Absence of suitable veins for blood sampling and administration of study intervention.
- Any other condition that would compromise safety of the participants.
- Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.
Phase IIa:
-
Known hypersensitivity to any component of the study intervention.
-
History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.
-
Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.
-
Hemoglobin < 9 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
-
Serum albumin of < 3 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
-
Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.
-
Known S aureus infection within 90 days of study entry.
-
Known acute viral or bacterial infection or symptoms/signs consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.
-
Participants with malignancy undergoing chemotherapy.
-
Scheduled date for living donor kidney transplant.
-
Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).
-
Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):
(a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.
(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.
(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase I: AZD7760 Dose A
Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Expérimental: Phase I: AZD7760 Dose B
Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Expérimental: Phase I: AZD7760 Dose C
Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Comparateur placebo: Phase I: Placebo
Participants will receive a single dose of placebo on Day 1. |
Participants will be administered placebo through intravenous infusion. |
|
Expérimental: Phase IIa: AZD7760 Dose D and Placebo
Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91. |
Participants will receive AZD7760 as a single intravenous infusion. Participants will be administered placebo through intravenous infusion. |
|
Expérimental: Phase IIa: AZD7760 Dose E
Participants will receive AZD7760 Dose E on Day 1 and Day 91. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Comparateur placebo: Phase IIa: Placebo
Participants will receive placebo on Day 1 and on Day 91. |
Participants will be administered placebo through intravenous infusion. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase I: Occurence of adverse events (AEs)
Délai: Day 1 to Day 181
|
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C. |
Day 1 to Day 181
|
|
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Délai: Day 1 to Day 361
|
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C. |
Day 1 to Day 361
|
|
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
Délai: Day 1 to Day 181
|
To evaluate the safety of AZD7760 compared with placebo as:
|
Day 1 to Day 181
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase I: Maximum observed plasma (peak) drug concentration (Cmax)
Délai: Day 1 to Day 361
|
To characterize the pharmacokinetics (PK) of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)
Délai: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
Délai: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Délai: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)
Délai: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Apparent volume of distribution at steady state (Vss)
Délai: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Apparent volume of distribution at the terminal phase (Vz)
Délai: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Incidence of ADA
Délai: Day 1 to Day 361
|
To evaluate ADA responses to AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase IIa: Cmax
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: tmax
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: t1/2λz
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: AUClast
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: AUCinf
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Vss
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Vz
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum
Délai: Day 1 to Day 181 and Day 1 to Day 451
|
To evaluate ADA responses to AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Occurrence of AEs
Délai: Day 1 to Day 181
|
To evaluate the safety to Day 181 of AZD7760 administered as:
|
Day 1 to Day 181
|
|
Phase IIa: Occurrence of MAAEs, SAEs, and AESIs
Délai: Day 1 to Day 451
|
To evaluate the safety to Day 451 of AZD7760 administered as:
|
Day 1 to Day 451
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladie chronique
- Attributs de la maladie
- Infections
- Syndrome de réponse inflammatoire systémique
- Inflammation
- Insuffisance rénale
- Infections bactériennes à Gram positif
- Infections bactériennes
- Infections bactériennes et mycoses
- Insuffisance rénale chronique
- Conditions pathologiques, signes et symptômes
- Infections staphylococciques
- État septique
- Insuffisance rénale chronique
Autres numéros d'identification d'étude
- D7480C00001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .